Join Growin Stock Community!

Immutep limitedIMMP.US Overview

US StockHealthcare
(No presentation for IMMP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMMP AI Insights

IMMP Overall Performance

IMMP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMMP Recent Performance

-3.21%

Immutep limited

0.05%

Avg of Sector

-0.31%

S&P500

IMMP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMMP Key Information

IMMP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMMP Profile

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Price of IMMP

IMMP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMMP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
52.02
PB Ratio
3.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-943.86%
Net Margin
-1059.19%
Revenue Growth (YoY)
62.39%
Profit Growth (YoY)
-79.92%
3-Year Revenue Growth
52.91%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
52.02
PB Ratio
3.98
Price-to-FCF
-
Gross Margin
-943.86%
Net Margin
-1059.19%
Revenue Growth (YoY)
62.39%
Profit Growth (YoY)
-79.92%
3-Year Revenue Growth
52.91%
3-Year Profit Growth
-%

  • When is IMMP's latest earnings report released?

    The most recent financial report for Immutep limited (IMMP) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMMP's short-term business performance and financial health. For the latest updates on IMMP's earnings releases, visit this page regularly.

  • What is the operating profit of IMMP?

    According to the latest financial report, Immutep limited (IMMP) reported an Operating Profit of -46.03M with an Operating Margin of -763.7% this period, representing a growth of 11.06% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IMMP's revenue growth?

    In the latest financial report, Immutep limited (IMMP) announced revenue of 6.03M, with a Year-Over-Year growth rate of 91.46%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IMMP have?

    As of the end of the reporting period, Immutep limited (IMMP) had total debt of 1.21M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IMMP have?

    At the end of the period, Immutep limited (IMMP) held Total Cash and Cash Equivalents of 72.75M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IMMP's EPS continuing to grow?

    According to the past four quarterly reports, Immutep limited (IMMP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMMP?

    Immutep limited (IMMP)'s Free Cash Flow (FCF) for the period is -28.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 1.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.